Childhood schizophrenia

Reading File

Finding Sources

Searching PubMed

"childhood schizophrenia" OR "early-onset schizophrenia"

Reading File

Finding Sources

Reading File

Loading Image

I now have comprehensive content to write a thorough response. Let me compile everything.

Childhood-Onset Schizophrenia (COS)

Definition and Epidemiology

Childhood-onset schizophrenia (COS) is defined as schizophrenia with onset before age 13 (some texts use before 17); onset before 5 is virtually nonexistent. It is a rare condition - incidence is less than 1 in 10,000 - making it far less common than adult schizophrenia. There is a slight male predominance (M:F ratio approximately 1.67:1). COS is considered a more severe form of the disease, with higher rates of premorbid abnormalities and a generally worse prognosis than adult-onset schizophrenia.

Kaplan and Sadock's Synopsis of Psychiatry, p. 669
Kaplan & Sadock's Comprehensive Textbook of Psychiatry, p. 10891

Etiology and Risk Factors

Genetic factors dominate. A family history of schizophrenia is markedly increased in COS. Healthy siblings of COS patients show gray matter deficits in left prefrontal and bilateral temporal cortices, suggesting familial/trait markers.

Neurodevelopmental factors:

Premorbid delays in motor milestones and language acquisition (resembling autism spectrum disorder features) are common
Prenatal and perinatal complications are not specifically increased (unlike ASD)
Exaggerated neuronal pruning is implicated in pathogenesis
COMT gene polymorphism may modulate frontal deficits

Environmental risk factors: Psychosocial/family stressors (high expressed emotion - "high EE" families) are known to influence relapse rate.

Pathophysiology and Neuroimaging

COS shows more severe neurobiological changes than adult schizophrenia, making it a valuable model for studying schizophrenia neurobiology:

Gray and white matter:

Smaller total brain volume (even more dramatic than in adults)
Progressive loss of gray and white matter in periventricular regions: posterior cingulate, caudate, thalamus
Slower growth of parietal white matter
Reduced fractional anisotropy in the cuneus (also seen in healthy siblings)

Prefrontal cortex / insula / temporal lobe:

Lower NAA (neuronal marker) and reduced gray matter in frontal and anterior cingulate cortices
Smaller right and left insula volumes; right insula inversely correlates with positive symptoms
Smaller superior temporal gyrus volumes - correlate with symptom severity; normalize somewhat after pharmacotherapy
Siblings show reduced activation of frontal and striatal regions (cortical-striatal dysfunction as a liability marker)

Hippocampus and amygdala:

Significant bilateral hippocampal volume deficit (~9-10%), persisting from age 9-26
Anterior hippocampal inward deformation correlates with positive symptoms
Amygdala-hippocampal volume reduction found in patients AND unaffected relatives

Subcortical structures:

Increased caudate volume (partly due to typical neuroleptic exposure - normalizes with clozapine)
Decreased thalamic volume - one of the most consistent findings in psychotropic-naïve patients

The figure below from the NIMH longitudinal study demonstrates progressive gray matter loss in COS compared to healthy controls:

Gray matter maturation in COS vs. healthy controls (NIMH longitudinal study). Panel A shows normal GM maturation from childhood to adulthood. Panel B shows global GM loss in COS. Panel C shows progressive COS vs. control differences from ages 12-24, with widespread cortical thinning worsening over time.

FIGURE: Right lateral views of (A) normal gray matter maturation in healthy youth ages 4-22, (B) global gray matter loss in COS vs. controls, and (C) progressive GM deficits in COS from ages 12 to 24 - showing that COS follows an exaggerated form of normal cortical maturation. - Kaplan & Sadock's Comprehensive Textbook, p. 10892

Clinical Features

All symptoms seen in adult schizophrenia can occur in children, but presentation differs based on developmental level:

Positive Symptoms

Hallucinations are the most common feature:

Auditory hallucinations predominate - voices may offer running commentary, command the child to harm themselves or others, or sound like "a computer in my head," "Martians," or familiar relatives
The NIMH COS project found unexpectedly high rates of tactile, olfactory, and visual hallucinations - visual ones (seeing devils, skeletons, scary faces) are associated with lower IQ and earlier onset
Visual, tactile, and olfactory hallucinations are markers of more severe psychosis

Delusions occur in up to 50% of children and adolescents:

Types: persecutory, grandiose, religious
Content is developmentally influenced - young children have simpler delusions featuring age-appropriate fears (monsters, animals); older children develop more complex ones
Frequency increases with age

Thought disorder:

Loosening of associations, thought blocking, illogical thinking, poverty of thought
Unlike adults, children do NOT show poverty of speech content but speak less and communicate more ambiguously
Failure to self-correct (no self-initiated repair) is a distinctive communication deficit

Negative Symptoms

Blunted or inappropriate affect (near universal) - giggling for no reason, crying inexplicably
Avolition, apathy, social withdrawal
Academic and social decline

Premorbid Features

Social rejection, poor peer relationships, clingy/withdrawn behavior
Academic difficulties
Some children show delayed motor milestones and language acquisition similar to ASD
Comorbid ADHD and conduct disorder are common

Differential Diagnosis

Condition	Key Distinguishing Features
Autism Spectrum Disorder (ASD)	Early developmental onset; poor social relatedness; stereotypies; no hallucinations/delusions as core features; seizures in 4-32%; no family history of schizophrenia
Bipolar I Disorder	1/3 of children initially diagnosed COS are later rediagnosed with bipolar disorder in adolescence; better long-term prognosis
Substance-induced psychosis	Amphetamines, LSD, PCP can cause paranoid psychosis; sudden flagrant onset is a clue
Medical causes	Thyroid disease, SLE, temporal lobe epilepsy
Anxiety/PTSD	Anxious children can have quasi-delusional thinking; PTSD flashbacks can mimic hallucinations
Depression/mania	Mood disorders can include nihilistic/grandiose delusions
Intellectual disability	Global impairments in verbal and nonverbal; relates socially per mental age

Kaplan and Sadock's Synopsis of Psychiatry, p. 404 (Table 2-13)

Course and Prognosis

COS generally carries a guarded prognosis - worse than adult-onset schizophrenia. Key predictors:

Poor prognostic factors:

Early age of onset and insidious onset
Family history of schizophrenia
Premorbid developmental delays, lower IQ, lower functioning
Comorbid ADHD or conduct disorder
Long or chronic first psychotic episode
High expressed emotion (high EE) in the family

Moderating factors: Response to pharmacological and psychosocial interventions, degree of remission after first episode, degree of family support.

The NIMH Treatment of Early-Onset Schizophrenia study (comparing molindone, olanzapine, and risperidone) found modest but significant improvement in neurocognitive functioning with antipsychotic treatment over 1 year, with no significant differences among the three agents.

Treatment

Treatment requires a multimodal approach.

Psychosocial Interventions

Psychoeducation for families - ongoing family therapeutic interventions are critical; high EE predicts relapse
CBT - effective component of integrated psychological intervention (IPI)
Group skills training and cognitive remediation therapy
Multifamily psychoeducation
Appropriate educational placement - addressing frequent social skills deficits, attention deficits, and academic difficulties
An RCT of integrated psychological interventions (IPI) in early prodromal youth was more effective than standard treatment in delaying psychosis onset over 2 years

Pharmacotherapy

Second-generation antipsychotics (SGAs) are the first-line treatment. Six RCTs support their efficacy in early-onset schizophrenia, with limited evidence favoring one agent over another.

Agent	Notes
Risperidone	FDA-approved for schizophrenia in adolescents; increases frontal activation (unlike typicals)
Olanzapine	Compared to clozapine in a double-blind RCT; significant weight gain concern
Aripiprazole	FDA-approved for adolescents
Quetiapine	Used in practice; sedation profile can be limiting
Lurasidone	FDA-approved for adolescents (2017)
Paliperidone	FDA-approved for adolescents (2017)
Clozapine	Most effective for positive AND negative symptoms, but last resort due to side effects (agranulocytosis, seizures, metabolic effects); normalizes caudate volume after switching from typicals

Important caveats in children:

Children have less robust responses to antipsychotics than adolescents and adults
Use the lowest effective dosage - children are more vulnerable to side effects
Greater vulnerability to extrapyramidal symptoms (EPS) with D2 antagonists
Greater risk of weight gain and metabolic abnormalities with SGAs
Antipsychotic drugs may impair learning in this population
Typical neuroleptics decrease frontal cortical activation; atypicals (e.g., risperidone) increase frontal activation

Key Comparison: COS vs. ASD

Feature	ASD	COS (before puberty)
Age of onset	Early developmental	Rarely under age 5
Incidence	~1%	<1 in 10,000
M:F ratio	4:1	1.67:1
Family Hx of schizophrenia	Not increased	Increased
Perinatal complications	Increased	Not increased
Core symptoms	Poor social relatedness, stereotypies, language abnormalities	Hallucinations, delusions, thought disorder
Adaptive functioning	Impaired	Deterioration from baseline
IQ	Wide range; 30% intellectually disabled	Usually normal/low average
Seizures	4-32%	Low incidence

Kaplan and Sadock's Synopsis of Psychiatry, p. 404

Sources:

Kaplan & Sadock's Comprehensive Textbook of Psychiatry (10th ed.), Chapter 37, pp. 10891-10894
Kaplan and Sadock's Synopsis of Psychiatry, pp. 669-676

This is a shared conversation. Sign in to Orris to start your own chat.